From Complexity to Clarity: Navigating C2-C6 Disease with Varithena — UIP 2023
Hear Drs. Misaki Kiguchi, Michael Shao, and Vinay Satwah share their real-world experiences treating chronic venous insufficiency with Varithena. The cases include tortuous anatomy, venous leg ulcers and varicose veins, and a combined case of superficial and deep venous disease.
VIEW-VLU study
See results from the recently published VIEW-VLU study showing the treatment effect of Varithena on venous leg ulcers.
Order
Varithena
Add to your practice with this versatile, efficient, and consistent varicose vein treatment. Order directly from Boston Scientific.
Become Varithena certified
Join the 2,000+ certified physicians improving patients’ lives with Varithena. We’re here to help you, and becoming certified is easy.
Contact a sales representative
Have your local Varithena
sales representative
contact you.
Join the physician
finder
Patients want to know who’s performing Varithena procedures. Get noticed by potential patients.
Indications
Varithena (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
Important Safety Information
The use of Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease. Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra- arterial injection of polidocanol occurs, consult a vascular surgeon immediately. Varithena can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis. Physicians administering Varithena must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena.
For Full Prescribing Information visit Varithena.com
Varithena™ is a registered trademark of Boston Scientific. All other trademarks are property of their respective owners.
PI-1269703-AA